Neptune vs. Aker Biomarine

 In the press release, Neptune claims infringement of U.S. Patent No. 6,800,299. According to information fra Aker BioMarine tha company has not yet received and read the filing, the biotechnology company is well aware of Neptune's patents in general and this process patent in particular. Aker BioMarine continuously analyzes the patent space to ensure freedom to operate and constructed the Superba(TM) production process specifically to avoid any patented process steps. - We regard this as a frivolous lawsuit, says Hallvard Muri, CEO of Aker BioMarine. But it was not entirely unexpected since we are aware that Neptune has repeatedly threatened several of our current and potential future customers with patent infringement lawsuits should they consider switching to Superba(TM). Our customers can rest sured that we welcome the opportunity to face Neptune in court over this patent and that we will support our customers should they be attacked by Neptune now or in the future.